Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$200.24 USD

200.24
266,099

-0.96 (-0.48%)

Updated Nov 7, 2024 10:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Mark Vickery headshot

BLS Jobs Up Big: 353K, 3.7% Unemployment

353K new jobs created for January are nearly double the 180K or so analysts were looking for.

AbbVie (ABBV) Reports Q4 Earnings: What Key Metrics Have to Say

The headline numbers for AbbVie (ABBV) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Kinjel Shah headshot

4 Large Drug Stocks Trying to Survive the Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retaining in one's portfolio.

AbbVie (ABBV) Q4 Earnings and Revenues Top Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 1.09% and 1.78%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Merck (MRK) Beats Q4 Earnings Estimates

Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

Eli Lilly (LLY) Earnings Expected to Grow: Should You Buy?

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Unveiling AbbVie (ABBV) Q4 Outlook: Wall Street Estimates for Key Metrics

Evaluate the expected performance of AbbVie (ABBV) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Derek Lewis headshot

3 Stocks Enjoying Favorable Analyst Coverage

All three of these stocks have seen upgrades from analysts in recent days. Is it time to buy?

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

The latest trading day saw AbbVie (ABBV) settling at $163.91, representing a -0.3% change from its previous close.

Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Should WisdomTree U.S. High Dividend ETF (DHS) Be on Your Investing Radar?

Style Box ETF report for DHS

Gilead (GILD) Down as NSCLC Study Fails to Meet Primary Goal

Gilead Sciences' (GILD) phase III study evaluating Trodelvy (sacituzumab govitecan) in previously treated metastatic NSCLC fails to meet its primary endpoint. Shares decline on the same.

AbbVie (ABBV) Exceeds Market Returns: Some Facts to Consider

AbbVie (ABBV) closed at $165.39 in the latest trading session, marking a +0.38% move from the prior day.

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors

Apple, AbbVie, Toyota Motor, Monster Beverage and General Motors are included in this Analyst Blog.

AbbVie (ABBV) Registers a Bigger Fall Than the Market: Important Facts to Note

In the closing of the recent trading day, AbbVie (ABBV) stood at $161.48, denoting a -0.57% change from the preceding trading day.

Sheraz Mian headshot

Q4 Earnings Season Scorecard and Analyst Reports for Apple, AbbVie & Toyota

Today's Research Daily features a real-time update on the Q4 earnings season and new research reports on Apple (AAPL), AbbVie (ABBV), Toyota Motor (TM) and others.

Is First Trust Value Line Dividend ETF (FVD) a Strong ETF Right Now?

Smart Beta ETF report for FVD

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More

Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion

Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie (ABBV) Ascends While Market Falls: Some Facts to Note

The latest trading day saw AbbVie (ABBV) settling at $162.31, representing a +0.55% change from its previous close.

Cytokinetics (CYTK) Rises on Reports of Buyout by Novartis

Cytokinetics (CYTK) shares gain on reports of acquisition by pharma giant Novartis.